Full text is available at the source.
Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea
Jul 15, 2015The Cochrane database of systematic reviews
How opioid, sleep, and sedative medicines affect breathing during sleep in adults with obstructive sleep apnea
AI simplified
Abstract
A total of 293 participants across 14 studies were analyzed regarding the effects of various sedative and hypnotic drugs on obstructive sleep apnoea (OSA).
- No significant increase in the apnoea-hypopnoea index (AHI) or the 4% oxygen desaturation index (ODI) was observed with the drugs studied.
- Eszopiclone 3 mg and sodium oxybate 4.5 g were associated with a significant reduction in AHI compared to placebo.
- Significant decreases in minimum nocturnal oxygen saturation were observed with zolpidem 20 mg, flurazepam 30 mg, remifentanil, and triazolam 0.25 mg.
- Remifentanil infusion did not significantly change AHI but decreased obstructive apnoeas and increased central apnoeas.
- Adverse events were reported in a subset of participants, indicating that the drugs were generally well tolerated despite some side effects.
AI simplified
BACKGROUND: Obstructive sleep apnoea (OSA) is a common sleep disorder characterised by partial or complete upper airway occlusion during sleep, leading to intermittent cessation (apnoea) or reduction (hypopnoea) of airflow and dips in arterial oxygen saturation during sleep. Many patients with recognised and unrecognised OSA receive hypnotics, sedatives and opiates/opioids to treat conditions including pain, anxiety and difficulty sleeping. Concerns have been expressed that administration of these drugs to people with co-existing OSA may worsen OSA.
OBJECTIVES: To investigate whether administration of sedative and hypnotic drugs exacerbates the severity of OSA (as measured by the apnoea-hypopnoea index (AHI) or the 4% oxygen desaturation index (ODI)) in people with known OSA.
SEARCH METHODS: We searched the Cochrane Airways Group Specialised Register (CAGR) of trials. The search was current as of March 2015.
SELECTION CRITERIA: Randomised, placebo-controlled trials including adult participants with confirmed OSA, where participants were randomly assigned to use opiates or opioids, sedatives, hypnotics or placebo. We included participants already using continuous positive airway pressure (CPAP) or a mandibular advancement device.
DATA COLLECTION AND ANALYSIS: We used standard methodological procedures as recommended by The Cochrane Collaboration.
MAIN RESULTS: Fourteen studies examining the effects of 10 drugs and including a total of 293 participants contributed to this review. Trials were small, with only two trials, which used sodium oxybate, recruiting more than 40 participants, and all but three trials were of only one to three nights in duration. Most participants had mild to moderate OSA with a mean AHI of 11 to 25 events/h, and only two trials recruited patients with severe OSA. Two trials investigating the effects of ramelteon, a treatment option for insomnia, recruited adults over 60 years of age with OSA and concomitant insomnia.The drugs studied in this review included remifentanil (infusion) 0.75 mcg/kg/h, eszopiclone 3 mg, zolpidem 10 and 20 mg, brotizolam 0.25 mg, flurazepam 30 mg, nitrazepam 10 mg to 15 mg, temazepam 10 mg, triazolam 0.25 mg, ramelteon 8 mg and 16 mg and sodium oxybate 4.5 g and 9 g. We were unable to pool most of the data, with the exception of data for eszopiclone and ramelteon.None of the drugs in this review produced a significant increase in AHI or ODI. Two trials have shown a beneficial effect on OSA. One study showed that a single administration of eszopiclone 3 mg significantly decreased AHI compared with placebo (24 ± 4 vs 31 ± 5; P value < 0.05), and a second study of sodium oxybate 4.5 g showed a significant decrease in AHI compared with placebo (mean difference (MD) -7.41, 95% confidence interval (CI) -14.17 to -0.65; N = 48).Only four trials reported outcome data on ODI. No significant increase, in comparison with placebo, was shown with eszopiclone (21 (22 to 37) vs 28.0 (15 to 36); P value = NS), zolpidem (0.81 ± 0.29 vs 1.46 ± 0.53; P value = NS), flurazepam (18.6 ± 19 vs 19.6 ± 15.9; P value = NS) and temazepam (6.53 ± 9.4 vs 6.56 ± 8.3; P value = 0.98).A significant decrease in minimum nocturnal peripheral capillary oxygen saturation (SpO2) was observed with zolpidem 20 mg (76.8 vs 85.2; P value = 0.002), flurazepam 30 mg (81.7 vs 85.2; P value = 0.002), remifentanil infusion (MD -7.00, 95% CI -11.95 to -2.05) and triazolam 0.25 mg in both rapid eye movement (REM) and non-REM (NREM) sleep (MD -14.00, 95% CI -21.84 to -6.16; MD -10.20, 95% CI -16.08 to -4.32, respectively.One study investigated the effect of an opiate (remifentanil) on patients with moderate OSA. Remifentanil infusion did not significantly change AHI (MD 10.00, 95% CI -9.83 to 29.83); however it did significantly decrease the number of obstructive apnoeas (MD -9.00, 95% CI -17.40 to -0.60) and significantly increased the number of central apnoeas (MD 16.00, 95% CI -2.21 to 34.21). Similarly, although without significant effect on obstructive apnoeas, central apnoeas were increased in the sodium oxybate 9 g treatment group (MD 7.3 (18); P value = 0.005) in a cross-over trial.Drugs studied in this review were generally well tolerated, apart from adverse events reported in 19 study participants prescribed remifentanil (n = 1), eszopiclone (n = 6), sodium oxybate (n = 9) or ramelteon (n = 3).
AUTHORS' CONCLUSIONS: The findings of this review show that currently no evidence suggests that the pharmacological compounds assessed have a deleterious effect on the severity of OSA as measured by change in AHI or ODI. Significant clinical and statistical decreases in minimum overnight SpO2 were observed with remifentanil, zolpidem 20 mg and triazolam 0.25 mg. Eszopiclone 3 mg and sodium oxybate 4.5 g showed a beneficial effect on the severity of OSA with a reduction in AHI and may merit further assessment as a potential therapeutic option for a subgroup of patients with OSA. Only one trial assessed the effect of an opioid (remifentanil); some studies included CPAP treatment, whilst in a significant number of participants, previous treatment with CPAP was not stated and thus a residual treatment effect of CPAP could not be excluded. Most studies were small and of short duration, with indiscernible methodological quality.Caution is therefore required when such agents are prescribed for patients with OSA, especially outside the severity of the OSA cohorts and the corresponding dose of compounds given in the particular studies. Larger, longer trials involving patients across a broader spectrum of OSA severity are needed to clarify these results.
Related papers
Jun '13
Medicine treatments for adults with blocked airway sleep apnea
cited by 44 papers
systematic review
Jan '20
Anti-inflammatory drugs for treating blocked breathing during sleep in children
cited by 27 papers
systematic review
Apr '06
Medicine treatments for adults with obstructive sleep apnea
cited by 57 papers
systematic review
Nov '20
Throat muscle exercises for treating obstructive sleep apnea
cited by 41 papers
systematic review
Dec '19
Using pressure changes or added moisture to improve continuous positive airway pressure use in adults with obstructive sleep apnea
cited by 14 papers
systematic review
Mar '23
Drug treatments for adult central sleep apnea
cited by 6 papers
systematic review
May '19
Using body position to reduce breathing pauses in obstructive sleep apnea
cited by 33 papers
systematic review
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 21 papers
systematic review
Oct '18
Eszopiclone for treating insomnia
cited by 31 papers
systematic review
Oct '22
Using non-invasive air pressure support to treat central sleep apnea in adults
cited by 7 papers
systematic review